Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Japan to send troops to help stop bear attacks
29/10/2025
A Nazi tattoo exposes Democrats' greatest weakness
29/10/2025
Quess Corp Q2 Results : Revenue up 3%, headcount rises by 21,000
29/10/2025
Automakers hunt high and low for chips as supply crisis worsens
29/10/2025
Akasa Air will look at IPO in next 2-5 years, says CEO Vinay Dube
29/10/2025
SAIL shares surge 8% to record high ahead of Q2 results. Should you buy, sell or hold ?
29/10/2025
